LFST vs TDOC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LFST and TDOC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LFST and TDOC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

LifeStance Health Group runs outpatient mental healthcare at national scale. Founded in 2017 and public since June 2021, the company employs licensed therapists, psychologists, psychiatrists and psychiatric nurse practitioners through its subsidiaries and supported practices, then routes patients to them through in-network insurance relationships. Care is delivered both in person and virtually, from more than ~550 centers spread across ~33 states, and volume reached roughly ~2.6 million patient visits in the second quarter of 2026 alone. Unlike cash-pay teletherapy apps, LifeStance is built around commercial insurance: about ~88% of revenue comes from commercial payors, ~7% from government programs and ~4% from self-pay, which means reimbursement rates negotiated with health plans, not consumer subscription pricing, set the revenue line.

Full LFST guide

Teladoc Health makes money through two reporting segments. Integrated Care sells virtual-care services (general medical, chronic-condition management for diabetes and hypertension via the former Livongo programs, expert medical opinions, and licensable platform tools) mostly to employers, health plans, and hospitals on a per-member-per-month and visit-fee basis; in 2025 it was the larger and more profitable engine, with Q1 2026 revenue of about ~$395 million and a roughly ~14% adjusted EBITDA margin. BetterHelp is a direct-to-consumer online mental-health and therapy subscription brand whose paying-member count and revenue have been falling; BetterHelp revenue declined about ~9% to roughly ~$950 million in 2025 and its segment adjusted EBITDA fell about ~46% to roughly ~$42 million as marketing costs rose, prompting a pivot toward insurance-reimbursed therapy.

Full TDOC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LFST drivers: Clinician headcount plus productivity, compounding together; Operating leverage on a largely fixed center and corporate base.
• TDOC drivers: Integrated Care and chronic-condition management; Free cash flow and balance-sheet discipline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. For TDOC, revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LFST if you believe its drivers more; TDOC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LFST and TDOC guides.

LFST. Pricing reflects the inflection rather than the trailing profit. Full-year 2026 guidance of ~$215M to ~$235M in adjusted EBITDA against an enterprise value near ~$4.79B works out to roughly ~21x the midpoint, a very different figure from the ~92x trailing GAAP multiple, and the gap between those two numbers is essentially stock compensation, amortization and litigation costs added back. Cash of ~$226M against ~$276M of term loan principal leaves the balance sheet close to neutral.

TDOC. Teladoc is now valued at a fraction of its 2021 peak, reflecting years of flat-to-declining revenue and the Livongo writedowns rather than a growth multiple. With GAAP losses ongoing, investors tend to focus on adjusted EBITDA and free cash flow as the practical yardsticks. All figures are approximate and tied to the asOf date; check the latest filings for current numbers.

Headline figures (approximate, August 2026): LFST shows revenue (ttm) ~$1.58B, up ~20% year over year, net income (ttm) ~$51M, or ~$0.13 per share, adjusted ebitda (q2 2026) ~$66M, ~15.2% of revenue, free cash flow (ttm) ~$174M; TDOC shows revenue (fy2025) ~$2,530 million, down ~2% from ~$2,570 million in 2024, segment mix Integrated Care ~$1,580 million; BetterHelp ~$950 million (FY2025), adjusted ebitda (fy2025) roughly ~$270 to ~$287 million (within guidance), free cash flow FY2025 outlook ~$170 to ~$185 million; FY2026 guidance ~$130 to ~$170 million.

LFST and TDOC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LFST and TDOC exposure against your real portfolio. It is not an investment adviser.